Aarkstore -Glycan Inhibitors -Pipeline Insights, 2014

1
Glycan Inhibitors -Pipeline Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/73729/glycan-inhibitors-pipeline-insights-2014

2
Summary

• DelveInsights,Glycan Inhibitors-Pipeline
  Insights, 2014, report provides comprehensive
  insights about pipeline drugs across this
  mechanism of action (MOA). A key objective of the
  report is to establish the understanding for all
  the pipeline drugs that fall under Glycan
  Inhibitors. This report provides information on
  the therapeutic development based on the Glycan
  Inhibitors dealing with mechanism of action,
  comparative analysis at various stages covering
  Filed, Phase III, Phase II, Phase I, IND filed,
  Preclinical, Discovery and unknown stages,
  therapeutics assessment by monotherapy and
  combination products and molecule type drug
  information. The report also covers the companies
  information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action. 

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Glycan InhibitorsThe
  report provides pipeline products under drug
  profile section which includes product
  description, MOA, licensors collaborators,
  development partner and chemical
  informationCoverage of the Glycan Inhibitors
  pipeline on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for Glycan
  Inhibitors and also provide company profilingThe
  report also gives the information of dormant and
  discontinued pipeline projects Pipeline products
  coverage based on various stages of development
  ranging from preregistration till discovery and
  undisclosed stages Provides pipeline assessment
  by monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for Glycan InhibitorsIdentify the
  relationship between the drugs and use it for
  target finding, drug repurposing, and precision
  medicine.Devise corrective measures for pipeline
  projects by understanding Glycan Inhibitors
  pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based
  Decisions

7
Table of Content

• Glycan Inhibitors OverviewGlycan Inhibitors
  Disease AssociatedGlycan Inhibitors Pipeline
  TherapeuticsGlycan Inhibitors Therapeutics under
  Development by Companies Glycan Inhibitors Late
  Stage Products (Filed and Phase III)Comparative
  Analysis Glycan Inhibitors Mid Clinical Stage
  Products (Phase II)Comparative Analysis Glycan
  Inhibitors Early Clinical Stage Products (Phase I
  and IND Filed)Comparative Analysis Glycan
  Inhibitors Discovery and Pre-Clinical Stage
  Products Comparative Analysis Drug Candidate
  ProfilesGlycan Inhibitors Therapeutics
  Assessment Assessment by Monotherapy Products 

8
Table of Content

• Assessment by Combination Products Assessment by
  Route of Administration Assessment by Molecule
  Type Glycan Inhibitors Discontinued
  Products Glycan Inhibitors Dormant
  ProductsCompanies Involved in Therapeutics
  Development for Glycan Inhibitors Appendix Metho
  dology Contact Us Disclaimer

9
List of Tables

• Number of Products under Development for Glycan
  Inhibitors by Therapy Area, 2014Number of
  Products under Development for Glycan Inhibitors,
  2014Number of Products under Development by
  Companies Comparative Analysis by Late Clinical
  Stage Products (Filed and Phase III),
  2014Comparative Analysis Mid Clinical Stage
  Products (Phase II), 2014Comparative Analysis
  Early Clinical Stage Products (Phase I and IND
  Filed), 2014Comparative Analysis Discovery and
  Pre-Clinical Stage Products, 2014Drug Candidates
  ProfilesGlycan Inhibitors Assessment by
  Monotherapy Products 

10
List of Tables

• Glycan Inhibitors Assessment by Combination
  Products Glycan Inhibitors Assessment by Route
  of Administration Glycan Inhibitors Assessment
  by Stage and Route of Administration Glycan
  Inhibitors Assessment by Molecule Type Glycan
  Inhibitors Assessment by Stage and Molecule
  Type Glycan Inhibitors Therapeutics Discontinued
  Products Glycan Inhibitors Therapeutics Dormant
  ProductsProducts under Development by Companies,
  2014

11
List of Figures

• Number of Products under Development for Glycan
  Inhibitors by Therapy Area, 2014Number of
  Products under Development for Glycan Inhibitors,
  2014Late Clinical Stage Products (Filed and
  Phase III), 2014Mid Clinical Stage Products
  (Phase II), 2014Early Clinical Stage Products
  (Phase I and IND Filed), 2014Discovery and
  Pre-Clinical Stage Products, 2014Glycan
  Inhibitors Assessment by Monotherapy
  Products Glycan Inhibitors Assessment by
  Combination Products Glycan Inhibitors
  Assessment by Route of Administration Glycan
  Inhibitors Assessment by Stage and Route of
  Administration Glycan Inhibitors Assessment by
  Molecule Type Glycan Inhibitors Assessment by
  Stage and Molecule Type

12
Related Reports

• OncoPlex Diagnostics - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• MetaStat, Inc. - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Advanced Cell Diagnostics, Inc. - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Recordati S.p.A. (REC) - Pharmaceuticals
  Healthcare - Deals and Alliances Profile
• Global Gene Expression Market 2015-2019
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Glycan Inhibitors -Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,Glycan Inhibitors-Pipeline
  Insights, 2014, report provides comprehensive
  insights about pipeline drugs across this
  mechanism of action (MOA).
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news